To the Editor: With regard to the results of the ADAURA trial reported by Wu et al. (Oct. 29 issue),¹ it is of interest to know whether chemotherapy is necessary when osimertinib is used as adjuvant therapy in patients with epidermal growth factor receptor (EGFR) mutation–positive resected stage IB, II, or IIIA non–small-cell lung cancer (NSCLC). Some previous studies involving Asian patients with NSCLC — half of whom had EGFR mutation–positive NSCLC — suggested that survival was shorter among patients who received adjuvant chemotherapy than among those who did not. These findings resemble the results in Figure S4 of the . . .